Dr. Nutt is a global expert on neuroscience and has devoted his career to the development of responses to the health problems associated with addiction, anxiety, and other psychiatric diseases. He has also pioneered research on the use of Positron Emission Tomography (PET) scanning techniques to explore the different receptors in the brain involved in these conditions. As founder of the Psychopharmacology Unit at Bristol University, Dr. Nutt has led cutting edge research into the brain mechanisms underlying anxiety, depression and addiction and the mode of action of therapeutic drugs. He has published more than 400 original research articles on these and related topics. His current research focuses predominantly on the brain circuits and receptors involved in addiction and in the discovery of new treatments. In addition, he is a practising psychiatrist, the Editor of the Journal of Psychopharmacology, advisor to the British National Formulary, a Past-President of the British Association of Psychopharmacology (BAP), and a former Chairman of the United Kingdom’s Advisory Council on the Misuse of Drugs. He has recently set up in the UK a new independent scientific group to assess drug harms: the ISCD.